Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.

BioMed research international - 1 Jan 2013

Halimeh Susan, Bidlingmaier Christoph, Heller Christine, Gutsche Sven, Holzhauer Susanne, Kenet Gili, Kurnik Karin, Manner Daniela, Iorio Alfonso, Nowak-Göttl Ulrike

Abstract excerpt

Among the discussed risk factors for high-titre inhibitor (HRI) development in patients with hemophilia A (HA) are high dose FVIII replacement therapy and use of recombinant FVIII concentrates (rFVIII). The aim of this study was to evaluate the aforementioned risk factors for HRI development in children with hemophilia A ≤2%. About 288 ascertained PUPs (Israel and Germany) were followed after initial HA diagnosis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child, Preschool
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Hemophilia A

Share to Infant

Share to Infant, Newborn

Share to Multivariate Analysis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 24199202
DOI: 10.1155/2013/901975
PMCID: PMC3807559

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.PMID 24199202Read ↗

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.Semantic proximity Read ↗

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.Semantic proximity Read ↗

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.Semantic proximity Read ↗

Treatment related factors and inhibitor development in children with severe haemophilia A.Semantic proximity Read ↗

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?Semantic proximity Read ↗

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Semantic proximity Read ↗

A close insight to factor VIII inhibitor in the congenital hemophilia A.Semantic proximity Read ↗

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.Semantic proximity Read ↗

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study.Semantic proximity Read ↗

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.Semantic proximity Read ↗

Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.Semantic proximity Read ↗

Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.